Headlines about AVEO Pharmaceuticals (NASDAQ:AVEO) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. AVEO Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.6092644214449 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Several research firms have commented on AVEO. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. B. Riley began coverage on shares of AVEO Pharmaceuticals in a research report on Monday, November 13th. They issued a “buy” rating and a $5.00 target price for the company. BidaskClub downgraded shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday. began coverage on shares of AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $5.00 target price for the company. Finally, Seaport Global Securities reissued a “buy” rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $4.05.

AVEO Pharmaceuticals (NASDAQ:AVEO) traded up $0.33 during mid-day trading on Friday, reaching $3.10. 3,620,000 shares of the company’s stock traded hands, compared to its average volume of 1,148,508. The company has a debt-to-equity ratio of -0.32, a current ratio of 2.33 and a quick ratio of 2.33. The company has a market capitalization of $327.75, a P/E ratio of -4.37 and a beta of 1.14. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $4.24.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2018/01/13/aveo-pharmaceuticals-aveo-receives-media-impact-rating-of-0-09.html.

About AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Insider Buying and Selling by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.